Patents by Inventor Shawn D. Britt

Shawn D. Britt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8691758
    Abstract: The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: April 8, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Shawn D. Britt, Kevin M. Cottrell, Robert B. Perni, Janos Pitlik
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20130116169
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 7, 2012
    Publication date: May 9, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Organic compounds and their uses
    Patent number: 8222425
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: July 17, 2012
    Assignee: Novartis AG
    Inventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 8217048
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: July 10, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • ORGANIC COMPOUNDS AND THEIR USES
    Publication number: 20110275819
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: July 19, 2011
    Publication date: November 10, 2011
    Applicant: NOVARTIS AG
    Inventors: Shawn D. BRITT, Lech Andrzej CISZEWSKI, Jiping FU, Subramanian KARUR, Yugang LIU, Peichao LU, David Thomas PARKER, Mahavir PRASHAD, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Aregahegn YIFRU, Rui ZHENG
  • Organic compounds and their uses
    Patent number: 8008263
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: August 30, 2011
    Assignee: Novartis AG
    Inventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20110104115
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 28, 2010
    Publication date: May 5, 2011
    Applicant: VERTEX PHARMACEUTICALS INCOROPRATED
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. Van Drie
  • Organic Compounds and their uses
    Publication number: 20100240638
    Abstract: The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection.
    Type: Application
    Filed: February 19, 2008
    Publication date: September 23, 2010
    Inventors: Shawn D. Britt, Jiping Fu, David Thomas Parker, Michiael Patane, Parkash Raman, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brand, Sylvain Cottens, Claus Ehrhardt, Stefan Andreas Randl, Pascal Rigollier, Nikolaus Schiering, Oliver Simic
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7745444
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: June 29, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Organic Compounds and Their Uses
    Publication number: 20090137495
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: October 10, 2008
    Publication date: May 28, 2009
    Inventors: Shawn D. Britt, Lech Andrzej Ciszewski, Jiping Fu, Subramanian Karur, Yugang Liu, Peichao Lu, David Thomas Parker, Mahavir Prashad, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20080311079
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: April 10, 2008
    Publication date: December 18, 2008
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7378422
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: May 27, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7109172
    Abstract: The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: September 19, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Shawn D. Britt, Kevin M. Cottrell, Robert B. Perni, Janos Pitlik
  • Inhibitors of bace
    Publication number: 20030095958
    Abstract: The present invention relates to inhibitors of aspartic proteinases, particularly, BACE. The present invention also relates to compositions thereof and methods therewith for inhibiting BACE activity in a mammal, and for treating Alzheimer's Disease and other BACE-mediated diseases.
    Type: Application
    Filed: April 29, 2002
    Publication date: May 22, 2003
    Inventors: Govinda R. Bhisetti, Jeffrey O. Saunders, Mark A. Murcko, Christopher A. Lepre, Shawn D. Britt, Jon H. Come, David D. Deininger, Tianshang Wang